<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="284">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513184</url>
  </required_header>
  <id_info>
    <org_study_id>DI/20/407/04/36</org_study_id>
    <nct_id>NCT04513184</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19</brief_title>
  <official_title>Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edda Sciutto Conde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General de México Dr. Eduardo Liceaga</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional Autonoma de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Clinical Trial evaluates nasal administration of Dexamethasone as an adjuvant treatment
      strategy for non-critically ill hospitalized participants with SARS CoV-2 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 30% of the admitted patients with Covid-19 require admission to the intensive
      care unit for respiratory assistance, ranging from a high flow nasal cannula to invasive
      ventilation. These patients are affected by respiratory dysfunctions and even dysfunction of
      the brain respiratory control centers. Additionally, exacerbated inflammation leads to
      endothelial and coagulation disorders that aggravate the course of the illness. No effective
      therapy has yet been found to treat forms SARS-CoV-2 bass. One of the adjunctive therapeutic
      alternatives addressed is the use of intravenously administered glucocorticoids (GC), aimed
      at reducing exacerbated peripheral inflammation. They have been used at early stages of
      infection in high doses and with controversial results. In our laboratory at the Biomedical
      Research Institute from the National Autonomous University of Mexico (UNAM), we have shown
      that dexamethasone, a GC (DXM) administered intranasally, reaches the central nervous system
      through the olfactory nerve (alike various pathogens, including coronaviruses) and reduces
      neuroinflammation more effectively than when applied intravenously. Additionally,
      biodistribution studies indicate that the DXM is detectable from the first minute after its
      application, both in the central nervous system and in the respiratory system. The objective
      of this study is to evaluate the safety, efficacy and tolerability of dexamethasone in
      patients hospitalized with SARS-CoV-2 with moderate-severe forms, with an without the
      requirement of mechanic ventilation, including syndrome of acute respiratory distress or
      pneumonia (as diagnosed by CAT) with alveolar / interstitial lung involvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, controlled trial adult patients with confirmed COVID-19 infection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of clinical improvement</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Evaluation of the clinical status of patients after randomization, defined as a two point improvement in the WHO 7-point Ordinal Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-death from all causes</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>All-cause mortality rates at 28 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time free from mechanical ventilation</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Ventilator-free days, defined as alive and not requiring mechanical ventilation, at 10 days after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Virological measurements, including proportions with detection of viral RNA over time and measurements of viral RNA titer area under the curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>Length of hospital stay in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Standard therapy (ST) only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control. Standard care and treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DXM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal dexamethasone plus Standard care and treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Dexamethasone</intervention_name>
    <description>6 mg from Day 1 to 10 after randomization</description>
    <arm_group_label>Standard therapy (ST) only</arm_group_label>
    <other_name>ST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasal Dexamethasone</intervention_name>
    <description>0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.</description>
    <arm_group_label>DXM</arm_group_label>
    <other_name>Nasal DXM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive diagnosis of SARS-CoV-2 by real-time RT-PCR in oropharyngeal sample.

          -  7 days or more after the start of the infection

          -  Hospitalized patients with moderate to severe respiratory complications that do not
             have received mechanical ventilation.

          -  Patients receiving standard therapy at the Hospital General de México Eduardo Liceaga.

          -  Signing of the informed consent form

          -  Patients of both sexes (non-pregnant female) 18 years of age or older will be eligible
             if they have a positive diagnostic sample by RT-PCR, pneumonia confirmed by chest
             imaging and oxygen saturation (SaO2) &lt; 93% at ambient air or a ratio of the partial
             pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) (PaO2: FiO2) at
             300 mg Hg or less

        Exclusion Criteria:

          -  Patients participating in another research protocol.

          -  Patients receiving oral or intravenous glucocorticoids

          -  Immunosuppressed patients (including HIV infection)

          -  Glaucoma patients.

          -  Patients with allergy to dexamethasone.

          -  Pregnant or lactating women

          -  Concomitant autoimmune diseases

          -  Refusal by the patient or family to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edda Sciutto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigaciones Biomédicas, UNAM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Graciela A Cárdenas-Hernández, PhD</last_name>
    <phone>+525556063822</phone>
    <phone_ext>2012</phone_ext>
    <email>gracielacardenas@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Chavez-Canales, PhD</last_name>
    <phone>525527282179</phone>
    <email>maria@iibiomedicas.unam.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Mexico Dr. Eduardo Liceaga</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana María H Espinosa-García, PhD</last_name>
      <phone>5527892000</phone>
      <phone_ext>1683</phone_ext>
      <email>anaesga@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Joselín Hernández-Ruiz, PhD</last_name>
      <phone>5527892000</phone>
      <phone_ext>1683</phone_ext>
      <email>hernandezjoselin@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología Ignacio Chávez</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Chávez-Canales, PhD</last_name>
      <phone>525527282179</phone>
      <email>maria@iibiomedicas.unam.mx</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>El Instituto Nacional de Neurologia Y Neurocirugia Manuel Velasco Suarez</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Graciela Cárdenas-Hernández, PhD</last_name>
      <phone>525556063822</phone>
      <phone_ext>2012</phone_ext>
      <email>gracielacardenas@yahoo.com.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Nacional Autonoma de Mexico</investigator_affiliation>
    <investigator_full_name>Edda Sciutto Conde</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>SARS CoV-2 infection</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Severe Acute Respiratory Syndrome</keyword>
  <keyword>Nasal administration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information exchange for research purposes</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Upon study completion, by request</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

